Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich’s ataxia and uncertainty about its functional benefits. The stock has dropped over ...
The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Guggenheim on March 25, 2025. The analyst firm set a price target for $26.00 expecting LRMR to rise to within 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback